Secukinumab and hidradenitis suppurativa: Friends or foes?

Classically, several therapeutic options have been described to treat patients affected by hidradenitis suppurativa (HS). Adalimumab is the only biologic approved by the US Food and Drug Administration available for therapy of moderate-to-severe HS. However, treatment may not always get the desired results, and adverse events may be possible. Alternative therapies are being studied for HS, including treatments using the interleukin (IL)-17A inhibitor.1 We report the potential double pathogenetic face of secukinumab in HS, describing a case of secukinumab-induced HS in a psoriasis patient successfully treated with adalimumab, and a case of HS and related psoriasiform eruption caused by adalimumab treatment, controlled by secukinumab therapy.